Browsing by Author "Bueno Ramírez, Susan "
Now showing 1 - 20 of 254
Results Per Page
Sort Options
- ItemA Herpes Simplex Virus Type 2 Deleted for Glycoprotein D Enables Dendritic Cells to Activate CD4(+) and CD8(+) T Cells(2017) Retamal Díaz, Angello Ricardo; Kalergis Parra, Alexis Mikes; Bueno Ramírez, Susan; González, P.
- ItemA Novel Live Vector Group A Streptococcal emm Type 9 Vaccine Delivered Intranasally Protects Mice against Challenge Infection with emm Type 9 Group A Streptococci(2014) Wozniak Banchero, Aniela; García Cañete, Patricia; Geoffroy, Enrique A.; Aguirre, Daniel B.; González, Samantha; Sarno, Victoria A.; Dale, James B.; Salazar Echegarai, Francisco Javier; Vera, Andrea Magdalena; Bueno Ramírez, Susan; Kalergis Parra, Alexis Mikes
- ItemA potential role of Salmonella infection in the onset of inflammatory bowel diseases(2017) Schultz, B.; Paduro, C.; Salazar, G.; Salazar Echegarai, F.; Sebastián Quijada, Valentina Pilar; Riedel, C.; Kalergis Parra, Alexis Mikes; Álvarez Lobos, M.; Bueno Ramírez, Susan
- ItemA single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice(2017) Céspedes, Pablo F.; Rey-Jurado, Emma; Espinoza Véliz, Janyra Alejandra; Rivera, Claudia A.; Canedo Marroquín, Gisela Eliana; Bueno Ramírez, Susan; Kalergis Parra, Alexis Mikes
- ItemAberrant T cell immunity triggered by human Respiratory Syncytial Virus and human Metapneumovirus infection(2017) González, A. E.; Lay, M. K.; Jara, E. L.; Espinoza, J. A.; Gómez, R. S.; Soto, J.; Rivera, C. A.; Abarca Villaseca, Katia; Bueno Ramírez, Susan; Riedel, C. A.; Kalergis Parra, Alexis Mikes
- ItemAcquired resistance to innate immune clearance promotes Klebsiella pneumoniae ST258 pulmonary infection(2016) Ahn, D.; Peñaloza Cerda, Hernán F.; Wang, Z.; Wickersham, M.; Parker, D.; Patel, P.; Koller, A.; Chen, E. I.; Bueno Ramírez, Susan; Uhlemann, A. C.; Prince, A.
- ItemActivation of regulator ArcA in the presence of hypochlorite in Salmonella enterica serovar Typhimurium(2021) Cabezas, C. E.; Laulié, A.M.; Briones, A. C.; Pardo Esté, C.; Lorca, D. E.; Cofré, A. A.; Morales, E. H.; Mora, A. Y.; Krüger, G. I.; Bueno Ramírez, Susan; Hidalgo, A. A.; Saavedra, C. P.
- ItemAdvancement in the development of mRNA-based vaccines for respiratory viruses(2024) Troncoso Bravo, Tays S.; Ramírez, Mario A.; Loaiza, Ricardo A.; Roman Cardenas, Carolina; Papazisis, Georgios; Garrido Cortés, Daniel; González, Pablo A.; Bueno Ramírez, Susan; Kalergis Parra, Alexis MikesAcute respiratory infections are the leading cause of death and illness in children under 5 years old and represent a significant burden in older adults. Primarily caused by viruses infecting the lower respiratory tract, symptoms include cough, congestion, and low-grade fever, potentially leading to bronchiolitis and pneumonia. Messenger ribonucleic acid (mRNA)-based vaccines are biopharmaceutical formulations that employ mRNA molecules to induce specific immune responses, facilitating the expression of viral or bacterial antigens and promoting immunization against infectious diseases. Notably, this technology had significant relevance during the COVID-19 pandemic, as these formulations helped to limit SARS-CoV-2 virus infections, hospitalizations, and deaths. Importantly, mRNA vaccines promise to be implemented as new alternatives for fighting other respiratory viruses, such as influenza, human respiratory syncytial virus, and human metapneumovirus. This review article analyzes mRNA-based vaccines' main contributions, perspectives, challenges, and implications against respiratory viruses.
- ItemAntibody development for preventing the human respiratory syncytial virus pathology.(2020) Soto Ramírez, Jorge Andrés; Gálvez Arriagada, Nicolás Marcelo Salvador; Pacheco, Gaspar A.; Bueno Ramírez, Susan; Kalergis Parra, Alexis MikesAbstract Human respiratory syncytial virus (hRSV) is the most important etiological agent causing hospitalizations associated with respiratory diseases in children under 5 years of age as well as the elderly, newborns and premature children are the most affected populations. This viral infection can be associated with various symptoms, such as fever, coughing, wheezing, and even pneumonia and bronchiolitis. Due to its severe symptoms, the need for mechanical ventilation is not uncommon in clinical practice. Additionally, alterations in the central nervous system -such as seizures, encephalopathy and encephalitis- have been associated with cases of hRSV-infections. Furthermore, the absence of effective vaccines or therapies against hRSV leads to elevated expenditures by the public health system and increased mortality rates for the high-risk population. Along these lines, vaccines and therapies can elicit different responses to this virus. While hRSV vaccine candidates seek to promote an active immune response associated with the achievement of immunological memory, other therapies -such as the administration of antibodies- provide a protective environment, although they do not trigger the activation of the immune system and therefore do not promote an immunological memory. An interesting approach to vaccination is the use of virus-neutralizing antibodies, which inhibit the entry of the pathogen into the host cells, therefore impairing the capacity of the virus to replicate. Currently, the most common molecule targeted for antibody design against hRSV is the F protein of this virus. However, other molecular components of the virus -such as the G or the N hRSV proteins- have also been explored as potential targets for the control of this disease. Currently, palivizumab is the only monoclonal antibody approved for human use. However, studies in humans have shown a protective effect only after the administration of at least 3 to 5 doses, due to the stability of this vaccine. Furthermore, other studies suggest that palivizumab only has an effectiveness close to 50% in high-risk infants. In this work, we will review different strategies addressed for the use of antibodies in a prophylactic or therapeutic context and their ability to prevent the symptoms caused by hRSV infection of the airways, as well as in other tissues such as the CNS.Abstract Human respiratory syncytial virus (hRSV) is the most important etiological agent causing hospitalizations associated with respiratory diseases in children under 5 years of age as well as the elderly, newborns and premature children are the most affected populations. This viral infection can be associated with various symptoms, such as fever, coughing, wheezing, and even pneumonia and bronchiolitis. Due to its severe symptoms, the need for mechanical ventilation is not uncommon in clinical practice. Additionally, alterations in the central nervous system -such as seizures, encephalopathy and encephalitis- have been associated with cases of hRSV-infections. Furthermore, the absence of effective vaccines or therapies against hRSV leads to elevated expenditures by the public health system and increased mortality rates for the high-risk population. Along these lines, vaccines and therapies can elicit different responses to this virus. While hRSV vaccine candidates seek to promote an active immune response associated with the achievement of immunological memory, other therapies -such as the administration of antibodies- provide a protective environment, although they do not trigger the activation of the immune system and therefore do not promote an immunological memory. An interesting approach to vaccination is the use of virus-neutralizing antibodies, which inhibit the entry of the pathogen into the host cells, therefore impairing the capacity of the virus to replicate. Currently, the most common molecule targeted for antibody design against hRSV is the F protein of this virus. However, other molecular components of the virus -such as the G or the N hRSV proteins- have also been explored as potential targets for the control of this disease. Currently, palivizumab is the only monoclonal antibody approved for human use. However, studies in humans have shown a protective effect only after the administration of at least 3 to 5 doses, due to the stability of this vaccine. Furthermore, other studies suggest that palivizumab only has an effectiveness close to 50% in high-risk infants. In this work, we will review different strategies addressed for the use of antibodies in a prophylactic or therapeutic context and their ability to prevent the symptoms caused by hRSV infection of the airways, as well as in other tissues such as the CNS.Abstract Human respiratory syncytial virus (hRSV) is the most important etiological agent causing hospitalizations associated with respiratory diseases in children under 5 years of age as well as the elderly, newborns and premature children are the most affected populations. This viral infection can be associated with various symptoms, such as fever, coughing, wheezing, and even pneumonia and bronchiolitis. Due to its severe symptoms, the need for mechanical ventilation is not uncommon in clinical practice. Additionally, alterations in the central nervous system -such as seizures, encephalopathy and encephalitis- have been associated with cases of hRSV-infections. Furthermore, the absence of effective vaccines or therapies against hRSV leads to elevated expenditures by the public health system and increased mortality rates for the high-risk population. Along these lines, vaccines and therapies can elicit different responses to this virus. While hRSV vaccine candidates seek to promote an active immune response associated with the achievement of immunological memory, other therapies -such as the administration of antibodies- provide a protective environment, although they do not trigger the activation of the immune system and therefore do not promote an immunological memory. An interesting approach to vaccination is the use of virus-neutralizing antibodies, which inhibit the entry of the pathogen into the host cells, therefore impairing the capacity of the virus to replicate. Currently, the most common molecule targeted for antibody design against hRSV is the F protein of this virus. However, other molecular components of the virus -such as the G or the N hRSV proteins- have also been explored as potential targets for the control of this disease. Currently, palivizumab is the only monoclonal antibody approved for human use. However, studies in humans have shown a protective effect only after the administration of at least 3 to 5 doses, due to the stability of this vaccine. Furthermore, other studies suggest that palivizumab only has an effectiveness close to 50% in high-risk infants. In this work, we will review different strategies addressed for the use of antibodies in a prophylactic or therapeutic context and their ability to prevent the symptoms caused by hRSV infection of the airways, as well as in other tissues such as the CNS.Abstract Human respiratory syncytial virus (hRSV) is the most important etiological agent causing hospitalizations associated with respiratory diseases in children under 5 years of age as well as the elderly, newborns and premature children are the most affected populations. This viral infection can be associated with various symptoms, such as fever, coughing, wheezing, and even pneumonia and bronchiolitis. Due to its severe symptoms, the need for mechanical ventilation is not uncommon in clinical practice. Additionally, alterations in the central nervous system -such as seizures, encephalopathy and encephalitis- have been associated with cases of hRSV-infections. Furthermore, the absence of effective vaccines or therapies against hRSV leads to elevated expenditures by the public health system and increased mortality rates for the high-risk population. Along these lines, vaccines and therapies can elicit different responses to this virus. While hRSV vaccine candidates seek to promote an active immune response associated with the achievement of immunological memory, other therapies -such as the administration of antibodies- provide a protective environment, although they do not trigger the activation of the immune system and therefore do not promote an immunological memory. An interesting approach to vaccination is the use of virus-neutralizing antibodies, which inhibit the entry of the pathogen into the host cells, therefore impairing the capacity of the virus to replicate. Currently, the most common molecule targeted for antibody design against hRSV is the F protein of this virus. However, other molecular components of the virus -such as the G or the N hRSV proteins- have also been explored as potential targets for the control of this disease. Currently, palivizumab is the only monoclonal antibody approved for human use. However, studies in humans have shown a protective effect only after the administration of at least 3 to 5 doses, due to the stability of this vaccine. Furthermore, other studies suggest that palivizumab only has an effectiveness close to 50% in high-risk infants. In this work, we will review different strategies addressed for the use of antibodies in a prophylactic or therapeutic context and their ability to prevent the symptoms caused by hRSV infection of the airways, as well as in other tissues such as the CNS.
- ItemAnticuerpo monoclonal Anti-N como una nueva terapia contra el Virus Respiratorio Sincicial Humano (VRSh) (Chile, concesión n° 67706)Kalergis Parra, Alexis Mikes; Bueno Ramírez, Susan
- ItemAnticuerpo monoclonal Anti-N como una nueva terapia contra el Virus Respiratorio Sincicial Humano (VRSh) (China, concesión n° CN 112912394B)Kalergis Parra, Alexis Mikes; Bueno Ramírez, Susan
- ItemAnticuerpos Monoclonales específicos para el antígeno M2-1 del Virus Respiratorio Sincicial (VRS), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por VRS (Alemania, concesión n° 2784088)Kalergis Parra, Alexis Mikes; Bueno Ramírez, Susan; Mora Alarcón, Jorge Eugenio; Gómez Johnson, Roberto Sebastian
- ItemAnticuerpos Monoclonales específicos para el antígeno M2-1 del Virus Respiratorio Sincicial (VRS), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por VRS (Bélgica, concesión n° 2784088)Kalergis Parra, Alexis Mikes; Bueno Ramírez, Susan; Mora Alarcón, Jorge Eugenio; Gómez Johnson, Roberto Sebastian
- ItemAnticuerpos Monoclonales específicos para el antígeno M2-1 del Virus Respiratorio Sincicial (VRS), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por VRS (Chile, concesión n° 50357)Kalergis Parra, Alexis Mikes; Bueno Ramírez, Susan; Mora Alarcón, Jorge Eugenio; Gómez Johnson, Roberto Sebastian
- ItemAnticuerpos Monoclonales específicos para el antígeno M2-1 del Virus Respiratorio Sincicial (VRS), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por VRS (China, concesión n° 201280062779.9)Kalergis Parra, Alexis Mikes; Bueno Ramírez, Susan; Mora Alarcón, Jorge Eugenio; Gómez Johnson, Roberto Sebastian
- ItemAnticuerpos Monoclonales específicos para el antígeno M2-1 del Virus Respiratorio Sincicial (VRS), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por VRS (España, concesión n° 2784088)Kalergis Parra, Alexis Mikes; Bueno Ramírez, Susan; Mora Alarcón, Jorge Eugenio; Gómez Johnson, Roberto Sebastian
- ItemAnticuerpos Monoclonales específicos para el antígeno M2-1 del Virus Respiratorio Sincicial (VRS), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por VRS (Francia, concesión n° 2784088)Kalergis Parra, Alexis Mikes; Bueno Ramírez, Susan; Mora Alarcón, Jorge Eugenio; Gómez Johnson, Roberto Sebastian
- ItemAnticuerpos Monoclonales específicos para el antígeno M2-1 del Virus Respiratorio Sincicial (VRS), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por VRS (Holanda, concesión n° 2784088)Kalergis Parra, Alexis Mikes; Bueno Ramírez, Susan; Mora Alarcón, Jorge Eugenio; Gómez Johnson, Roberto Sebastian
- ItemAnticuerpos Monoclonales específicos para el antígeno M2-1 del Virus Respiratorio Sincicial (VRS), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por VRS (India, concesión n° 317819)Kalergis Parra, Alexis Mikes; Bueno Ramírez, Susan; Mora Alarcón, Jorge Eugenio; Gómez Johnson, Roberto Sebastian
- ItemAnticuerpos Monoclonales específicos para el antígeno M2-1 del Virus Respiratorio Sincicial (VRS), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por VRS (Macao, concesión n° 201280062780)Kalergis Parra, Alexis Mikes; Bueno Ramírez, Susan; Mora Alarcón, Jorge Eugenio; Gómez Johnson, Roberto Sebastian